Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Karolin Behringer"'
Autor:
Esther Natalie Oliva, Tatyana Ionova, Edward Laane, Mario Csenar, Julia Schroer, Karolin Behringer, Ina Monsef, Annika Oeser, Nicole Skoetz, Sam Salek
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundLymphoma treatment can lead to long-term consequences such as fatigue, infertility and organ damage. In clinical trials, survival outcomes, clinical response and toxicity are extensively reported while the assessment of treatment on quality
Externí odkaz:
https://doaj.org/article/74def3ba426040b8872039bcd49b6d1a
Autor:
Johannes Rosenbrock, Andrés Vásquez-Torres, Horst Mueller, Karolin Behringer, Matthias Zerth, Eren Celik, Jiaqi Fan, Maike Trommer, Philipp Linde, Michael Fuchs, Peter Borchmann, Andreas Engert, Simone Marnitz, Christian Baues
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
IntroductionConsolidation radiotherapy in intermediate stage Hodgkin´s lymphoma (HL) has been the standard of care for many years as involved field radiotherapy (IFRT) after chemotherapy. It included initially involved region(s). Based on randomized
Externí odkaz:
https://doaj.org/article/a7c449e4676741c6898703e5368886a7
Autor:
Jesko Momotow, Helen Goergen, Karolin Behringer, Paul J. Bröckelmann, Sven Borchmann, Bastian v. Tresckow, Carsten Kobe, Andreas Engert, Stephanie Sasse
Publikováno v:
HemaSphere, Vol 3, Iss 5 (2019)
Externí odkaz:
https://doaj.org/article/6bf3cb51d40b414cb275f0c6438a869b
Autor:
Horst Müller, Carolin Bürkle, Peter Borchmann, Stefanie Kreissl, Helen Goergen, Anja Mehnert, Karolin Behringer, Michael Fuchs, Julia Meissner, Andreas Engert
Publikováno v:
Leukemia & Lymphoma. 60:1389-1398
We performed a survey in Hodgkin lymphoma survivors to learn more about their perspectives on treatment risks and benefits. We sent questions to 1149 survivors from the GHSG’s HD13-15 trials with (...
Autor:
Horst Müller, Bastian von Tresckow, Paul J Bröckelmann, Karolin Behringer, Michael Fuchs, Christian Baues, Peter Borchmann, Tom Vieler, Andreas Engert, Thomas Pabst, Alden A. Moccia, Martin Soekler, Andreas Rank, Teresa Guhl
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(2)
PURPOSE We evaluated disease and treatment characteristics of patients with relapse after risk-adapted first-line treatment of early-stage, favorable, classic Hodgkin lymphoma (ES-HL). We compared second-line therapy with high-dose chemotherapy and a
Autor:
Jürg Bernhard, Peter Borchmann, Horst Müller, Karolin Behringer, Helen Goergen, Richard Greil, Jana Markova, Julia Meissner, Michaela Möstl, Jens-Ulrich Rüffer, Volker Diehl, Max S. Topp, Martin Sökler, Bastian von Tresckow, Michael Fuchs, Andreas Engert, Stefanie Kreissl, Hans-Henning Flechtner
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(25)
PURPOSE Many important details of health-related quality of life (HRQoL) after diagnosis and treatment of Hodgkin lymphoma (HL) are still unknown because large longitudinal studies of HRQoL are rare. Therefore, we analyzed a systematically assessed,
Publikováno v:
Fertility Preservation in Oncological and Non-Oncological Diseases ISBN: 9783030475673
Hodgkin’s lymphoma occurs frequently in younger age. Fertility preservation is an important issue as survival rates are very high and some of the treatments are highly gonadotoxic.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::056744e8518767ce33b66ee240d4fb4d
https://doi.org/10.1007/978-3-030-47568-0_7
https://doi.org/10.1007/978-3-030-47568-0_7
Autor:
Michael von Wolff, Karolin Behringer
Publikováno v:
Hodgkin Lymphoma ISBN: 9783030324810
Hodgkin Lymphoma ISBN: 9783319125046
Hodgkin Lymphoma ISBN: 9783319125046
Patients with Hodgkin lymphoma (HL) are generally young, and high cure rates can be achieved. Thus, HL diagnosis and therapy frequently occur at a time of life when family planning plays an important role. It is therefore of major importance for the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7627fa2426ff61d5fd1208ad1fc42978
https://doi.org/10.1007/978-3-030-32482-7_28
https://doi.org/10.1007/978-3-030-32482-7_28
Autor:
Johannes C. Hellmuth, Carsten Kobe, Karolin Behringer, Andreas Engert, Michael Fuchs, Peter Borchmann, Max S. Topp, Martin Sökler, Annette Plütschow, Dennis A. Eichenauer, Stefanie Kreissl, Georg Kuhnert, Wolfram Klapper, Volker Diehl, Stephan Mathas, Julia Meissner, Markus Dietlein
Publikováno v:
The Lancet Oncology. 18:1680-1687
Summary Background A high proportion of patients with relapsed classical Hodgkin's lymphoma achieve a response with the antibody-drug conjugate brentuximab vedotin, and the drug is well tolerated. We modified the escalated BEACOPP regimen (eBEACOPP;
Autor:
Paul J Bröckelmann, Jesko Momotow, Bastian von Tresckow, Helen Goergen, Carsten Kobe, Andreas Engert, Stephanie Sasse, Sven Borchmann, Karolin Behringer
Publikováno v:
HemaSphere
HemaSphere, Vol 3, Iss 5 (2019)
HemaSphere, Vol 3, Iss 5 (2019)